Mounjaro UK: Eligibility Criteria, BMI Classification, Access Routes, and Next Steps
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist with demonstrated efficacy for significant weight reduction in adults with obesity. In the UK, access to Mounjaro for weight management is strictly defined by clinical eligibility criteria, with Body Mass Index (BMI) serving as the primary determinant.
Mounjaro Eligibility Under Proposed NHS England Criteria
As of October 2024, Mounjaro is not available on NHS prescriptions for weight loss. However, planned access pathways--pending NICE approval--require patients to meet one of the following conditions:
- BMI >= 40, or
- BMI between 35 and 39.9 with at least three of the following weight-related comorbidities:
- Hypertension
- Dyslipidemia
- Obstructive sleep apnea
- Cardiovascular disease
To interpret these thresholds, the full BMI classification used by UK health authorities is provided below.
Complete BMI Classification (WHO/NHS Standard)
| BMI Range | Classification |
|---|---|
| < 18.5 | Underweight |
| 18.5 -- 24.9 | Normal weight |
| 25.0 -- 29.9 | Overweight |
| 30.0 -- 34.9 | Class I Obesity |
| 35.0 -- 39.9 | Class II Obesity |
| >= 40.0 | Class III Obesity (Morbid Obesity) |
Only individuals with Class II Obesity (with comorbidities) or Class III Obesity meet the proposed criteria for Mounjaro access in the UK.
Real-time BMI Calculation
Calculate your Body Mass Index (BMI) to see which category you fall into.
Automatic real-time BMI calculator
NHS Availability Status
Mounjaro remains unavailable via NHS England for obesity treatment. A phased rollout is under consideration but requires formal health technology assessment and funding allocation.
Private Prescription Options
Regulated online clinics offer Mounjaro following a medical consultation with a GMC-registered clinician. The process includes verification of height, weight, BMI, and relevant medical history. Prescriptions are issued only when clinical suitability is confirmed.
Treatment Costs
Monthly pricing varies by dosage, reflecting the standard dose-escalation protocol:
| Dosage | Starting Price | Daily Cost |
|---|---|---|
| 2.5 mg | £110 | £3.66 |
| 5 mg | £141 | £4.70 |
| 7.5 mg | £186 | £6.20 |
| 10 mg | £206 | £6.86 |
| 12.5 mg | £222 | £7.40 |
| 15 mg | £237 | £7.90 |
Introductory discounts (e.g., £56 off first order) may be available through select providers, subject to clinical approval.
Private Insurance Coverage
Some private health insurance policies may cover Mounjaro if prescribed for an approved indication and supported by specialist documentation. Coverage is not guaranteed. Policyholders should verify formulary inclusion and pre-authorization requirements directly with their insurer.
Eli Lilly does not offer a patient assistance or savings program for Mounjaro in the UK.
Expected Weight Loss Outcomes (12--16 Weeks)
| Age Group | Avg. Weight Loss |
|---|---|
| 18--30 | 12%--15% |
| 31--40 | 10%--14% |
| 41--50 | 9%--12% |
| 51--60 | 8%--11% |
| 61+ | 6%--10% |
Individual results depend on baseline BMI, adherence, diet, and physical activity levels.
How to Access Mounjaro in the UK
Simple Steps
- Calculate your BMI using accurate height and weight.
- Confirm eligibility: BMI >= 40, or BMI 35--39.9 with at least three weight-related health conditions.
- Choose a regulated UK online clinic or private prescriber.
- Complete a medical consultation.
- If approved, receive your prescription and medication.
Verify Your Eligibility with a Clinician
BMI is a screening tool, not a diagnostic endpoint. A healthcare professional can confirm accurate BMI calculation using clinical measurements, assess the presence and severity of weight-related comorbidities, evaluate contraindications (e.g., personal or family history of medullary thyroid carcinoma), and determine whether Mounjaro aligns with overall health goals. Regulated UK providers require this assessment before prescribing.